Analysts See $-0.39 EPS for Corium International Inc (CORI)

July 28, 2017 - By Darrin Black

 Analysts See $ 0.39 EPS for Corium International Inc (CORI)
Investors sentiment increased to 0.86 in 2016 Q4. Its up 0.17, from 0.69 in 2016Q3. It is positive, as 5 investors sold Corium International Inc shares while 9 reduced holdings. 4 funds opened positions while 8 raised stakes. 9.28 million shares or 50.34% less from 18.69 million shares in 2016Q3 were reported.
Manufacturers Life Commerce The has 0% invested in Corium International Inc (NASDAQ:CORI). Parallax Volatility Advisers Ltd Partnership accumulated 0% or 1,783 shares. Moreover, Essex Inv Management Ltd Liability Co has 0.07% invested in Corium International Inc (NASDAQ:CORI) for 101,655 shares. Vanguard Group Inc has 0% invested in Corium International Inc (NASDAQ:CORI). Tower Rech Capital Lc (Trc) holds 0% of its portfolio in Corium International Inc (NASDAQ:CORI) for 1,017 shares. Massachusetts-based Putnam Investments Ltd Company has invested 0% in Corium International Inc (NASDAQ:CORI). Tci Wealth Advisors Inc reported 162 shares. Wall Street reported 0.57% stake. Geode Capital Ltd reported 69,108 shares. Blackrock Institutional Na owns 66,313 shares. Needham Mgmt Ltd Liability Corporation holds 0.62% or 597,824 shares. Retail Bank Of New York Mellon accumulated 0% or 11,586 shares. Northern Corp reported 19,304 shares. Senzar Asset Mngmt Ltd Co holds 1.7% or 1.58 million shares. Moreover, Goldman Sachs Group Inc Inc has 0% invested in Corium International Inc (NASDAQ:CORI).

Investors wait Corium International Inc (NASDAQ:CORI) to report on August, 3. its quarterly earnings Wall Street analysts expect $-0.39 earnings per share, down $0.05 or 14.71 % from last year’s $-0.34 same quarter earnings. Corium International Inc’s Wall Street analysts see -7.14 % EPS growth, taking into account the $-0.42 EPS reproted in the previous quarter, The stock decreased 3.56% or $0.31 during the last trading session, reaching $8.39. About 214,011 shares traded. Corium International Inc (NASDAQ:CORI) has risen 84.14% since July 28, 2016 and is uptrending. It has outperformed by 67.44% the S&P500.

Corium International Inc (NASDAQ:CORI) Ratings Coverage

Among 6 analysts covering Corium International (NASDAQ:CORI), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Corium International had 12 analyst reports since August 25, 2015 according to SRatingsIntel. The firm has “Buy” rating given on Wednesday, September 2 by Zacks. The firm has “Buy” rating given on Tuesday, August 25 by Zacks. The company was maintained on Tuesday, February 9 by Needham. The stock of Corium International Inc (NASDAQ:CORI) has “Buy” rating given on Friday, May 26 by Jefferies. The firm has “Hold” rating by WBB Securities given on Monday, August 31. The stock of Corium International Inc (NASDAQ:CORI) earned “Buy” rating by Jefferies on Monday, July 17. The rating was maintained by Needham on Monday, November 16 with “Buy”.

Corium International, Inc. is a commercial-stage biopharmaceutical firm focused on the development, manufacture and commercialization of specialty pharmaceutical products. The company has market cap of $292.24 million. As of September 30, 2016, the Company had multiple programs in preclinical and clinical development focused primarily on the treatment of neurological disorders, with two lead programs in Alzheimer’s disease. It currently has negative earnings. The Firm has two transdermal platforms: Corplex for small molecules and MicroCor, a biodegradable microstructure technology for small molecules and biologics, including vaccines, peptides and proteins.

More notable recent Corium International Inc (NASDAQ:CORI) news were published by: Globenewswire.com which released: “Corium to Present Clinical Results from Pilot Bioequivalence Study of Once …” on July 06, 2017, also Zacks.com with their article: “Corium International (CORI) Catches Eye: Stock Jumps 11.9% July 07, 2017” published on July 07, 2017, Globenewswire.com published: “Corium to Report Preliminary Results from Corplex Donepezil Pilot Study and …” on May 09, 2017. More interesting news about Corium International Inc (NASDAQ:CORI) were released by: Seekingalpha.com and their article: “Corium International Has A New Take On A Great Drug” published on May 01, 2017 as well as Seekingalpha.com‘s news article titled: “Corium International’s (CORI) CEO Peter Staple on Q1 2017 Results – Earnings …” with publication date: February 14, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: